The activity is consistent with routine option exercise and tax-related or planned sales rather than negative sentiment; monitor for further sales or commentary in upcoming filings. No material financial impact expected.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 20 $524.28entry
- T+1 · 8mo ago −0.58%α −1.63% · $521.22
- T+5 · 8mo ago −0.28%α +1.96% · $522.83
- T+20 · 7mo ago +9.38%α +0.10% · $573.44
- T+60 · 5mo ago +4.58%α −11.11% · $548.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics insiders, including CEO Martine Rothblatt and CFO James Edgemond, conducted a series of derivative exercises and open-market sales over the past week. The total open-market sales amounted to approximately $1.07 million, with the majority tied to option exercises at low strike prices, indicating planned equity realization rather than reactive selling.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 559 shares for $373,765 across multiple transactions at prices between $516.84 and $536.97.
- CFO James Edgemond sold 991 shares for $527,236; also exercised 20,000 derivative shares (10,000 at $135.42, 10,000 at $0).
- Director Tommy Thompson sold 275 shares for $147,845 and exercised 4,000 derivative shares.
- Director Judy Olian sold 200 shares for $106,000.
- Total open-market sales: $1,073,360; total derivative exercises: over $5.7 million in non-cash transactions.
- All sales represent a tiny fraction (0.0046%) of United Therapeutics' $23.3B market cap.
Financial Impact
$1.07 million in open-market sales and over $5.7 million in derivative exercises over 7 days
Risk Factors
- Perception of insider selling could weigh on sentiment if misinterpreted.
- Future sales could increase if insiders continue exercising options.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-UTHR-1774643538723 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers